IDT CORP (IDT) Form 8-K — Jun 11, 2026

$IDTForm 8-KItems 5.02, 9.01Filed Jun 11, 2026, 5:03 PM ET0001437749-26-020335Original filing

IDT Corporation announced the resignation of Irwin Katsof from its board of directors effective June 9, 2026. The company stated that the resignation was not the result of any disagreement regarding operations, policies, or practices. The board appointed William Conkling as a new director to fill the vacancy. Conkling, currently Chief Commercial Officer at Protara Therapeutics, brings extensive experience in pharmaceutical commercialization from previous roles at Rafael Holdings, Immunomedics, and Novartis.

Price after filing

1 day: 0.0%7 days: +0.7%30 days: +9.0%

Close on the filing date to close N calendar days later (from $55.04). Historical, not a forecast.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.